The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase I/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18.2 and 4-1BB, in patients with advanced solid tumors.
 
Ye Guo
Honoraria - BeiGene; Merck Serono; MSD; Roche
Consulting or Advisory Role - GlaxoSmithKline; Merck Serono; MSD; Roche
 
Lihua Wu
No Relationships to Disclose
 
Yong Li
No Relationships to Disclose
 
Jinhua Wen
No Relationships to Disclose
 
Junli Xue
No Relationships to Disclose
 
Zhuoyi Wang
No Relationships to Disclose
 
Pu Li
No Relationships to Disclose
 
Wei Zhao
No Relationships to Disclose
 
Jingfeng Liu
No Relationships to Disclose
 
Xi Rao
No Relationships to Disclose
 
Qun Li
No Relationships to Disclose
 
Liqiong Xue
No Relationships to Disclose
 
Xiaoxiao Ge
No Relationships to Disclose
 
Fengjuan Lin
No Relationships to Disclose
 
Wenbo Tang
No Relationships to Disclose
 
Jiuli Zhou
No Relationships to Disclose